The Pharmacokinetics of BSH Following Single and Multiple Administrations

In EORTC trial 11961 “Glioma Treatment with BNCT”, the treatment with BNCT is given in four fractions, on four consecutive days. Prior to each fraction, BSH (Na2B12H11SH) is infused in amounts such that 30ppm boron is reached as average over the four fractions. Before the BNCT treatment, BSH is administered at the time point of surgery, in order to gain data on the pharmacokinetics of BSH in the individual patient. On this basis, and assuming that each dosage of BSH is purely additive and that the pharmacokinetics of BSH at surgery is a good prediction of the pharmacokinetics at treat-ment, an individual prescription scheme can be established beforehand.